MHRA went from being “reactive passenger” to “suddenly becoming a driver” during pandemic, says CEO
The chief executive of the UK’s medicines regulator has announced plans to “further streamline and remove barriers” to clinical trials in the wake of Covid-19 to make it “an enabling regulator from now on”.
Speaking at the SV Health Investors Forum on 30 November, June Raine said the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) would soon be consulting on changes to clinical trial legislation to replace EU rules.